Is Gilead Sciences Inc Gaining or Losing Market Support? - Gilead Sciences ( NASDAQ:GILD )
Gilead Sciences Inc's ( NYSE:GILD ) short interest as a percent of float has risen 3.52% since its last report. According to exchange reported data, there are now 18.25 million shares sold short, which is 1.47% of all regular shares that are available for trading.
Market Whales and Their Recent Bets on GILD Options - Gilead Sciences ( NASDAQ:GILD )
Investors with a lot of money to spend have taken a bearish stance on Gilead Sciences ( NASDAQ:GILD ) . We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't ...
Gilead Sciences, Inc. ( GILD ) Is a Trending Stock: Facts to Know Before Betting on It
Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Is IPF the Next Big Market Opportunity for United Therapeutics?
UTHR reports strong TETON-2 results for Tyvaso in IPF, showing lung function gains and eyeing a major new market.
Is Veeva's Vault CRM Emerging as the Standard for Top Biopharma?
VEEV's Vault CRM is gaining traction with top biopharma firms like Merck, Gilead, and BMS, signaling its rise as the industry's commercial standard.
Kymera Overcomes Sanofi Deal Update, Marches Ahead With Pipeline
Kymera advances its protein degradation pipeline with new Sanofi and Gilead deals, milestone payouts, and promising trial updates.
Immatics Appoints Venkat Ramanan as Chief Financial Officer
Houston, Texas and Tuebingen, Germany, October 1, 2025 - Immatics N.V. ( NASDAQ: IMTX, "Immatics" or the "Company" ) , a clinical-stage biopharmaceutical company and the global leader in precision targeting of PRAME, today announced the appointment of Venkat Ramanan, Ph.D., as Chief Financial ...
Royalty Pharma Appoints Dr. Ted W. Love As Lead Independent Director
NEW YORK, Sept. 29, 2025 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) today announced that the independent directors of the Board have unanimously appointed Dr. Ted W. Love, an independent director since 2020, as Lead Independent Director.
Royalty Pharma Appoints Dr. Ted W. Love As Lead Independent Director - Royalty Pharma ( NASDAQ:RPRX )
NEW YORK, Sept. 29, 2025 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( NASDAQ: RPRX ) today announced that the independent directors of the Board have unanimously appointed Dr. Ted W. Love, an independent director since 2020, as Lead Independent Director.
Hanmi's Oral Delivery Platform Compound Licensed to Gilead
SEOUL, South Korea, Sept. 29, 2025 /PRNewswire/ -- Hanmi Pharm announced on September 29 that it has entered into a global licensing and collaboration agreement with Gilead Sciences, Inc. ( "Gilead" ) and Health Hope Pharma ( "HHP" ) granting Gilead the exclusive rights to develop and ...
Gilead Sciences ( GILD ) Declines More Than Market: Some Information for Investors
Gilead Sciences (GILD) concluded the recent trading session at $110.99, signifying a -2.36% move from its prior day's close.
Gilead Sciences Surges 26.5% YTD: Buy, Sell or Hold the Stock?
Gilead surges 26.5% YTD in 2025 as HIV franchise gains momentum with Yeztugo approval, offsetting cell therapy pressures.
If You Invested $100 In Gilead Sciences Stock 20 Years Ago, You Would Have This Much Today - Gilead Sciences ( NASDAQ:GILD )
Gilead Sciences GILD has outperformed the market over the past 20 years by 3.06% on an annualized basis producing an average annual return of 11.85%. Currently, Gilead Sciences has a market capitalization of $142.31 billion.
Gilead Sciences ( GILD ) Outpaces Stock Market Gains: What You Should Know
Gilead Sciences (GILD) concluded the recent trading session at $113.59, signifying a +1.19% move from its prior day's close.
Investors Heavily Search Gilead Sciences, Inc. ( GILD ) : Here is What You Need to Know
Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Fangzhou Wins Gilead 'Award of Excellence' for AI-Driven Chronic Disease Management
Fangzhou received the "Excellence Award" at Gilead Sciences, Inc.'s ("Gilead") 2025 Multi-Channel Conference in Shanghai.
Gilead Sciences ( GILD ) Ascends While Market Falls: Some Facts to Note
Gilead Sciences (GILD) reached $112.26 at the closing of the latest trading day, reflecting a +1.26% change compared to its last close.
Gilead Sciences ( GILD ) Exceeds Market Returns: Some Facts to Consider
In the latest trading session, Gilead Sciences (GILD) closed at $117.86, marking a +2.26% move from the previous day.
Gilead Sciences Commits to Veeva Vault CRM - Veeva Systems ( NYSE:VEEV )
Next generation CRM with deep capabilities and agentic AI PLEASANTON, Calif., Sept. 10, 2025 /PRNewswire/ -- Veeva Systems VEEV today announced that Gilead Sciences has committed to Veeva Vault CRM.
Is Invesco Pharmaceuticals ETF ( PJP ) a Strong ETF Right Now?
Smart Beta ETF report for ...
WACO Theater Center Announces Still Here Live Experience In Los Angeles Supported By Gilead Sciences, Inc.
An interactive installation and immersive performance rooted in the stories of Black women and HIV-brought to life inside a working hair salon.
Aisera Named a Visionary in 2025 Gartner® Magic Quadrant™ for AI Applications in IT Service Management
SANTA CLARA, Calif., Sept. 05, 2025 ( GLOBE NEWSWIRE ) -- Aisera, a leading provider of agentic AI for the enterprise, announced today that it has been recognized for the second straight year by Gartner, specifically as a Visionary in the 2025 Gartner® Magic Quadrant™ for Artificial Intelligence ...
Pharming Group appoints Kenneth Lynard as Chief Financial Officer
Leiden, the Netherlands, September 2, 2025: Pharming Group N.V. ( "Pharming" or "the Company" ) ( Euronext: PHARM. Nasdaq: PHAR ) today announced the appointment of Kenneth Lynard as Chief Financial Officer ( CFO ) , effective October 1, 2025.
Pharming Group appoints Kenneth Lynard as Chief Financial Officer - Pharming ( NASDAQ:PHAR )
Leiden, the Netherlands, September 2, 2025: Pharming Group N.V. ( "Pharming" or "the Company" ) ( PHARMPHAR today announced the appointment of Kenneth Lynard as Chief Financial Officer ( CFO ) , effective October 1, 2025.
Here is What to Know Beyond Why Gilead Sciences, Inc. ( GILD ) is a Trending Stock
Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
GILD Wins Approval for Twice-Yearly HIV Prevention Shot in the EU
Gilead secures EU approval for twice-yearly HIV prevention shot Yeytuo, backed by strong trial data and expanded market protection.
I-Mab Announces the Appointment of Seasoned Biotech Executives to the Board of Directors and the Scientific Advisory Board, and the Formation of a Research and Development Committee - I-MAB ( NASDAQ:IMAB )
Dr. Robert Lenz, Ms. Xin Liu and Dr. Sean Cao appointed to the Board of Directors Research and Development Committee established to accelerate innovation and long-term growth Dr. Ken Takeshita appointed to the Scientific Advisory Board
Here's How Much You Would Have Made Owning Gilead Sciences Stock In The Last 20 Years - Gilead Sciences ( NASDAQ:GILD )
Gilead Sciences GILD has outperformed the market over the past 20 years by 4.08% on an annualized basis producing an average annual return of 12.81%. Currently, Gilead Sciences has a market capitalization of $142.44 billion.
GILD Stock Slips as CVS Health Excludes New HIV Drug Yeztugo
Gilead shares slip after CVS refused to add its new HIV drug, Yeztugo, while its Kite unit struck a $350 million deal with Interius BioTherapeutics.
Gildea's Kite Pharma Just Acquired Interius-$350 Million Move Shakes Up Cancer Therapy - Gilead Sciences ( NASDAQ:GILD )
Kite will acquire Interius BioTherapeutics for $350 million, expanding into in vivo CAR T therapies. The deal is expected to cut Gilead's 2025 EPS by 23-25 cents per share. Get more market-moving news first with AI-powered analysis that turns noise into opportunity.
Why Is Gilead Sciences Stock Falling Thursday? - CVS Health ( NYSE:CVS ) , Gilead Sciences ( NASDAQ:GILD )
CVS rejects Gilead's $28K-a-year HIV prevention drug Yeztugo from coverage. The federal judge ordered CVS Caremark to pay nearly $290 million in Medicare fraud cases. Get more market-moving news first with AI-powered analysis that turns noise into opportunity. CVS Health Inc.
Why Is Walgreens Stock Gaining Tuesday? - Walgreens Boots Alliance ( NASDAQ:WBA )
Walgreens Specialty Pharmacy adds HIV, dermatitis, and cancer drugs in 2025. Independence from PBMs enables wider partnerships across healthcare. Get more market-moving news first with AI-powered analysis that turns noise into opportunity. Walgreens Boots Alliance, Inc.
Inhibikase Therapeutics Strengthens Leadership Team with Appointment of Timothy Pigot as Chief Commercial and Strategy Officer - Inhibikase Therapeutics ( NASDAQ:IKT )
BOSTON and ATLANTA, Aug. 19, 2025 ( GLOBE NEWSWIRE ) -- Inhibikase Therapeutics, Inc.
GILD Stock Up 7% Post Q2 Earnings: Should You Buy Now or Wait?
Gilead's Q2 earnings beat and raised 2025 outlook lift shares 7.3%, fueled by HIV gains, Trodelvy strength, and new PrEP launch Yeztugo.
Is iShares Biotechnology ETF ( IBB ) a Strong ETF Right Now?
Smart Beta ETF report for ...
Is Trending Stock Gilead Sciences, Inc. ( GILD ) a Buy Now?
Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Will Breyanzi's Strong Uptake Help BMY Offset Generic Competition?
Bristol Myers' Breyanzi sales surged 125% in Q2 to $344M, fueled by new approvals, strong demand and expanded market reach.
Ligand Announces Pricing of $400 Million Convertible Senior Notes Offering - Ligand Pharmaceuticals ( NASDAQ:LGND )
JUPITER, Fla., Aug. 11, 2025 ( GLOBE NEWSWIRE ) -- Ligand Pharmaceuticals Incorporated LGND ( "Ligand" ) announced today the pricing of $400.0 million aggregate principal amount of 0.75% convertible senior notes due 2030 ( the "notes" ) in a private placement ( the "offering" ) to persons ...
Ligand Announces Pricing of $400 Million Convertible Senior Notes Offering
JUPITER, Fla., Aug. 11, 2025 ( GLOBE NEWSWIRE ) -- Ligand Pharmaceuticals Incorporated ( Nasdaq: LGND ) ( "Ligand" ) announced today the pricing of $400.0 million aggregate principal amount of 0.75% convertible senior notes due 2030 ( the "notes" ) in a private placement ( the "offering" ) to ...
3 Biotech Stocks Likely to Outpace Q2 Earnings Estimates
Zevra, Inovio and Journey Medical are set for potential earnings beat this week, backed by strong products and positive ESP scores.
Ligand Announces Proposed Offering of $400 Million of Convertible Senior Notes Due 2030
Ligand Announces Proposed Offering of $400 Million of Convertible Senior Notes Due ...
Company News for Aug 11, 2025
Companies In The News Are: GILD, TTD, TXRH, GEN.
Why Is Gilead Sciences Stock Surging Friday? - Gilead Sciences ( NASDAQ:GILD )
Q2 adjusted EPS of $2.01 beat the $1.94 consensus; revenue hit $7.08 billion vs. $6.94 billion estimate. Biktarvy sales rose 9% to $3.5 billion; Descovy surged 35% to $653 million amid higher demand and pricing. Get ahead of next week's CPI & PPI with Chris Capre's live trading strategy session ...
SoundHound AI, Ouster, Globalstar, Doximity, JFrog And Other Big Stocks Moving Higher On Friday - Blue Gold ( NASDAQ:BGL ) , Astrana Health ( NASDAQ:ASTH )
U.S. stocks were higher, with the Dow Jones index gaining around 200 points on Friday. Shares of SoundHound AI, Inc. SOUN rose sharply during Friday's session after the company reported better-than-expected second-quarter financial results and raised its FY25 sales guidance above estimates.
GILD Stock Rises on Q2 Earnings and Sales Beat, '25 View Up
GILD tops Q2 earnings, raises 2025 guidance as HIV drugs Biktarvy and Descovy drive revenue growth.
Gilead Sciences ( GILD ) Q2 2025 Earnings Call Transcript
Image source: The Motley Fool.Thursday, August 7, 2025, at 4:30 p.m. ETNeed a quote from a Motley Fool analyst? Email [email protected] reading ...
Assembly Biosciences Announces Pricing of $175 Million in Equity Financings
SOUTH SAN FRANCISCO, Calif., Aug. 08, 2025 ( GLOBE NEWSWIRE ) -- Assembly Biosciences, Inc. ( "Assembly Bio" ) ( Nasdaq: ASMB ) , a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced the pricing of an underwritten, registered offering ( the ...
Gilead Sciences ( GILD ) Tops Q2 Earnings and Revenue Estimates
Gilead (GILD) delivered earnings and revenue surprises of +3.08% and +1.95%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
How To Earn $500 A Month From Gilead Sciences Stock Ahead Of Q2 Earnings - Gilead Sciences ( NASDAQ:GILD )
A more conservative goal of $100 monthly dividend income would require 380 shares of Gilead Sciences. An investor would need to own $209,422 worth of Gilead Sciences to generate a monthly dividend income of $500. The market's back, and these 3 income stocks are thriving. See them here→
Jobless Claims Increased More Than Expected
Another full morning of market data to go through today, which will help articulate where we are in several accounts of the massive U.S. economy. Pre-market futures were at peak highs just ahead of new economic prints this morning, but we remain in healthy, positive territory.
